Rethinking Clinical Trials

This chapter explores the intricate relationship between clinical trial methodologies and regulatory bodies like the FDA, emphasizing the potential advantages of decentralized trials for improving patient engagement and reducing costs. It critiques traditional practices for their inefficiencies and the inertia in the pharmaceutical industry that hampers innovation. The conversation also highlights the financial dynamics within the biotech sector, advocating for a shift towards more adaptive and collaborative approaches to drug discovery and trial processes.